	US 11,679,105 B1
	Pharmaceutical compositions of cabozantinib
Sushant Omprakash Dube, Maharashtra (IN); Suprit Dilip Saoji, Maharashtra (IN); Pankaj Kisan Chatki, Telangana (IN); Sumitra Ashokkumar Pillai, Telangana (IN); and Girish G. Kore, Maharashtra (IN)
Assigned to SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed by SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed on Feb. 10, 2023, as Appl. No. 18/108,423.
Application 18/108,423 is a continuation of application No. 17/673,583, filed on Feb. 16, 2022, granted, now 11,590,122.
Claims priority of application No. 202141007078 (IN), filed on Feb. 19, 2021.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/47 (2006.01); A61K 9/10 (2006.01)

CPC A61K 31/47 (2013.01) [A61K 9/10 (2013.01)]

13 Claims

1. A stable pharmaceutical composition comprising an amorphous solid dispersion of cabozantinib;

wherein said amorphous solid dispersion comprises: (a) cabozantinib; and (b) at least one pharmaceutically acceptable carrier,

wherein the level of total impurities is less than 2% w/w when stored at 40° C./75% RH for at least 6 months, and wherein a moisture content of the composition is controlled to be less than about 4.0% by weight.